Analyst Reco. Liquidia Corporation

Equities

LQDA

US53635D2027

Real-time Estimate Cboe BZX Other stock markets 18:35:33 09/05/2024 BST			5-day change	1st Jan Change
12.34 ^USD	-1.24%		-4.73%	+2.79%

04-01	Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	MT
04-01	Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing	03-20	MT
HC Wainwright Adjusts Price Target on Liquidia to $32 From $16, Maintains Buy Rating	03-14	MT
BofA Securities Raises Price Target on Liquidia to $15 From $13, Maintains Buy Rating	12-21	MT
Needham Adjusts Price Target on Liquidia to $18 From $16, Maintains Buy Rating	17/03/23	MT
Needham Raises Liquidia's Price Target to $16 From $12, Maintains Buy Rating	01/09/22	MT
Wedbush Lowers Liquidia to Underperform From Neutral, Price Target to $3 From $4 on Adjusted Yutrepia Timeline	01/09/22	MT
Ladenburg Thalmann Initiates Coverage of Liquidia at Buy with $15 Price Target	22/07/22	MT
BTIG Adjusts Liquidia's Price Target to $17 From $14, Reiterates Buy Rating	20/07/22	MT
BTIG Starts Liquidia at Buy With $14 Price Target	31/05/22	MT
BofA Securities Starts Liquidia at Buy With $12 Price Target	26/05/22	MT
Wedbush Cuts Price Target on Liquidia Technologies to $4 From $6, Following Tyvaso Regulatory Update, Maintains Neutral Rating	24/05/22	MT
Wedbush Cuts Price Target on Liquidia Technologies to $4 From $6, Citing Tyvaso Market Penetration Estimates, Maintains Neutral Rating	24/05/22	MT
HC Wainwright Adjusts Liquidia Technologies' Price Target to $16 From $6, Keeps Buy Rating	03/02/22	MT
Needham Adjusts Liquidia Technologies' Price Target to $12 from $8, Keeps Buy Rating	10/01/22	MT
Wedbush Lifts Liquidia Technologies' Price Target to $6 From $2; Neutral Rating Kept	09/11/21	MT
LIQUIDIA : Wedbush Adjusts Price Target for Liquidia Technologies to $2 From $3, Maintains Neutral Rating	13/05/21	MT
LIQUIDIA : Wedbush Adjusts Liquidia Technologies' PT to $3 From $2, Citing Subcutaneous Treprostinil for Pulmonary Arterial Hypertension; Neutral Rating Kept	31/03/21	MT
LIQUIDIA : Wedbush Adjusts Price Target on Liquidia Technologies to $2 From $4 on Lowered LIQ861/PAH Penetration Rate Estimates; Neutral Rating Kept	30/03/21	MT
LIQUIDIA : HC Wainwright Initiates Liquidia Technologies at Buy With $6 Price Target	04/12/20	MT
LIQUIDIA : Wedbush Cuts Liquidia Technologies to Neutral From Outperform on LIQ861 Regulatory Headwind, LIQ865 US Launch Timeline; PT to $4 From $20	20/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Liquidia Corporation

Equities

LQDA

US53635D2027

Analyst Reco.

Filters